First Foundation Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Foundation Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,377	Closed	-$327K	–	393
2022 Q4	$327K	Sell	1,377 -521	-27%	-$111K	0.02%	294
2022 Q3	$380K	Sell	1,898 -1,568	-45%	-$299K	0.02%	260
2022 Q2	$506K	Sell	3,466 -8,568	-71%	-$1.22M	0.02%	249
2022 Q1	$1.97M	Sell	12,034 -2,430	-17%	-$370K	0.07%	135
2021 Q4	$2.45M	Buy	14,464 +600	+4%	+$112K	0.08%	119
2021 Q3	$2.62M	Buy	13,864 +1,035	+8%	+$194K	0.1%	110
2021 Q2	$2.17M	Buy	12,829 +1,155	+10%	+$169K	0.08%	135
2021 Q1	$1.65M	Buy	+11,674	New	+$1.76M	0.07%	152

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

First Foundation Advisors's ALNY Position: Q1 2023 in Review

First Foundation Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 1,377 shares — an estimated $327K sold.

First Foundation Advisors first reported a position in ALNY in Q1 2021 and held it in 8 quarters. The position peaked at $2.62M in Q3 2021. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

First Foundation Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
First Foundation Advisors sold 1,377 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $327K.
First Foundation Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 8 quarters.
First Foundation Advisors's Alnylam Pharmaceuticals position peaked at $2.62M in Q3 2021.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on First Foundation Advisors's 13F filing for Q1 2023, filed 12 May 2023.